Skip to main content
Premium Trial:

Request an Annual Quote

Microfluidics Firm Arradial Secures $3M in Additional Series A Financing

NEW YORK, April 16 - Arradial, a spin-off of Alexion Pharmaceuticals that develops microfluidic-based microarray technology, today said it has secured $3 million in additional Series A financing from Oxford Bioscience Partners.

 

The company, based in Bedford, Mass., is also expected to announce tomorrow the appointment of John R. Havens as senior vice president of technology. Havens, who comes to Arradial from Nanogen, where he was senior director for chemistry and high-throughput screening, will help the firm develop and commercialize its microfluidics technology.

 

Yesterday, Arradial hired Mark A. Tepper president and CEO. Tepper was previously vice president for research and operations at the Serono Pharmaceutical Research Institute.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.